In the last trading session, 2.85 million shares of the Jasper Therapeutics Inc (NASDAQ:JSPR) were traded, and its beta was 2.77. Most recently the company’s share price was $3.02, and it changed around -$0.02 or -0.66% from the last close, which brings the market valuation of the company to $45.37M. JSPR currently trades at a discount to its 52-week high of $26.05, offering almost -762.58% off that amount. The share price’s 52-week low was $2.27, which indicates that the current value has risen by an impressive 24.83% since then. We note from Jasper Therapeutics Inc’s average daily trading volume that its 10-day average is 2.08 million shares, with the 3-month average coming to 463.10K.
Jasper Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.73. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended JSPR as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Jasper Therapeutics Inc is expected to report earnings per share of -1.32 for the current quarter.
Jasper Therapeutics Inc (NASDAQ:JSPR) trade information
Instantly JSPR has showed a red trend with a performance of -0.66% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.19 on recent trading dayincreased the stock’s daily price by 58.0%. The company’s shares are currently down -86.40% year-to-date, but still down -45.59% over the last five days. On the other hand, Jasper Therapeutics Inc (NASDAQ:JSPR) is -47.02% down in the 30-day period. We can see from the shorts that 1.54 million shares have been sold at a short interest cover period of 6.99 day(s).
The consensus price target as assigned by Wall Street analysts is $48, which translates to bulls needing to increase their stock price by 93.71% from its current value. Analyst projections state that JSPR is forecast to be at a low of $48 and a high of $48.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 54.53%. Jasper Therapeutics Inc earnings are expected to increase by 5.54% in 2025, but the outlook is positive 4.11% per year for the next five years.
JSPR Dividends
Jasper Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-12.
Jasper Therapeutics Inc (NASDAQ:JSPR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.27% of Jasper Therapeutics Inc shares, and 87.94% of them are in the hands of institutional investors. The stock currently has a share float of 89.07%. Jasper Therapeutics Inc stock is held by 104.0 institutions, with VELAN CAPITAL INVESTMENT MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 9.8216% of the shares, which is about 1.47 million shares worth $32.55 million.
SOLEUS CAPITAL MANAGEMENT, L.P., with 8.5157% or 1.28 million shares worth $28.97 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
T. Rowe Price Small-Cap Value Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 438.89 shares worth $1.33 million, making up 2.92% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 401.22 shares worth around $1.21 million, which represents about 2.67% of the total shares outstanding.
